MEDISEARCHER NEWS
European Union · Autoimmune disease · 15 November 2026
In brief
- The European Medicines Agency (EMA) has recommended expanding the use of Gazyvaro (obinutuzumab) to adults with moderate-to-severe, active systemic lupus erythematosus (SLE).
- The proposed indication covers patients who test positive for relevant autoantibodies and whose disease remains active despite standard treatment.
- The recommendation was adopted on 12 November 2026 and announced on 13 November.
- In the Phase 3 ALLEGORY trial, 76.7% of patients receiving Gazyvaro plus standard treatment achieved the primary response outcome after 52 weeks, compared with 53.5% receiving placebo plus standard treatment.
- Patients receiving Gazyvaro also experienced fewer lupus flares and were more likely to achieve sustained reductions in corticosteroid use.
- Infections, including respiratory and urinary tract infections, are important safety considerations.
- The expanded EU indication is not yet approved. A European Commission decision and subsequent national access arrangements are still required.
A treatment already used for certain cancers and lupus-related kidney disease could soon become available to a broader group of people with systemic lupus erythematosus (SLE) in Europe.
On 13 November 2026, the European Medicines Agency announced that its Committee for Medicinal Products for Human Use (CHMP) had recommended extending the authorised uses of Gazyvaro (obinutuzumab) to adults with moderate-to-severe, active, autoantibody-positive SLE whose disease remains inadequately controlled despite standard treatment.
The recommendation follows positive results from the Phase 3 ALLEGORY trial, which found significantly better disease control in patients receiving Gazyvaro alongside their existing treatment than in patients receiving placebo alongside standard treatment.
The findings are particularly relevant because lupus can cause recurring inflammatory flares, progressive organ damage and prolonged dependence on corticosteroids.
However, this is not a cure for lupus, and the new indication has not yet received final European Commission approval.
What is Gazyvaro (obinutuzumab)?
Gazyvaro is a biological medicine containing obinutuzumab, a monoclonal antibody that targets CD20, a protein found on certain B cells in the immune system.
B cells normally help protect the body against infection by producing antibodies and supporting immune responses.
In autoimmune diseases such as lupus, abnormal immune activity can contribute to the production of autoantibodies that attack the body’s own tissues.
By targeting CD20-positive B cells, obinutuzumab reduces their numbers and can help suppress immune processes involved in inflammation and tissue damage.
Gazyvaro is administered by intravenous infusion under medical supervision. It is not an oral medicine or a treatment that patients administer independently at home.
The medicine has been authorised in the European Union since 2014 for certain blood cancers, including chronic lymphocytic leukaemia and follicular lymphoma.
It is also already authorised for certain forms of active lupus nephritis, a serious kidney complication of lupus.
The November 2026 recommendation concerns a broader indication for systemic lupus erythematosus, rather than the medicine’s first European approval.
What exactly has the EMA recommended?
The EMA’s CHMP adopted a positive opinion on 12 November 2026 recommending Gazyvaro as an add-on therapy for:
Adults with moderate-to-severe, active, autoantibody-positive systemic lupus erythematosus despite standard therapy.
This means the proposed indication is intended for patients who continue to experience significant lupus activity even though they are already receiving appropriate treatment.
The recommendation does not mean every person diagnosed with lupus would be eligible.
Eligibility would depend on disease severity, autoantibody status, response to existing treatment, contraindications and the final authorised prescribing information.
The European Commission must still decide whether to approve the expanded indication.
What did the Phase 3 ALLEGORY trial show?
The EMA’s recommendation is supported by the ALLEGORY Phase 3 trial, published in the New England Journal of Medicine in March 2026.
The randomised, double-blind, placebo-controlled study enrolled 303 adults with active systemic lupus erythematosus despite standard treatment.
Participants were randomly assigned to receive:
- Obinutuzumab plus standard lupus treatment (151 patients); or
- Placebo plus standard lupus treatment (152 patients).
The main outcome was the proportion of patients achieving an SLE Responder Index-4 (SRI-4) response after 52 weeks.
SRI-4 is a composite measure of improvement in lupus disease activity. It requires a meaningful reduction in disease activity without certain forms of significant worsening or new organ involvement.
At 52 weeks:
- 76.7% of patients receiving obinutuzumab achieved an SRI-4 response.
- 53.5% of patients receiving placebo achieved the same outcome.
- The adjusted difference was 23.1 percentage points, with a 95% confidence interval of 12.5 to 33.6 percentage points.
- The primary result was statistically significant (P<0.001).
Both groups continued receiving standard lupus therapy, so these results demonstrate the additional benefit of obinutuzumab rather than its effectiveness as a replacement for all other treatment.
ALLEGORY trial results: Gazyvaro versus standard care
The following chart compares the primary treatment-response outcome with two additional measures of disease control reported in the trial.
Gazyvaro improves lupus disease control
ALLEGORY Phase 3 trial · Outcomes after 52 weeks
The results show that patients receiving obinutuzumab were more likely to experience meaningful improvement in disease activity than those receiving placebo.
The additional remission and low-disease-activity findings are encouraging, but they require careful interpretation. Remission in lupus is defined using clinical criteria and does not mean that the underlying autoimmune disease has been permanently eliminated.
The trial also reported statistically significant improvements across its key secondary outcomes, including sustained reduction in glucocorticoid dose and time to the first disease flare.
Could Gazyvaro help patients reduce steroid use?
One important aspect of the ALLEGORY findings is the potential to reduce reliance on corticosteroids.
Corticosteroids such as prednisone are commonly used to suppress inflammation during lupus flares and periods of active disease.
They can be effective, but prolonged use may contribute to complications including:
- Osteoporosis and fractures;
- Increased susceptibility to infections;
- Weight gain and metabolic complications;
- High blood pressure and elevated blood glucose; and
- Other long-term treatment-related harms.
Reducing corticosteroid exposure while maintaining disease control is therefore an important treatment objective.
In ALLEGORY, patients receiving obinutuzumab were more likely to achieve sustained reductions in glucocorticoid use while maintaining control of lupus disease activity.
That is a clinically relevant finding because it suggests the treatment may help some patients control their disease with less dependence on steroids.
However, patients should not reduce or stop prescribed corticosteroids independently. Dose reductions must be supervised, particularly after prolonged use.
Did Gazyvaro reduce lupus flares?
Yes. The ALLEGORY trial found that obinutuzumab performed better than placebo on the prespecified secondary outcome measuring time to the first lupus flare.
Lupus flares are periods when disease activity increases, potentially causing symptoms such as joint pain, fatigue, rashes or inflammation affecting internal organs.
Frequent or severe flares can interfere with everyday activities and may contribute to cumulative organ damage.
The trial’s results suggest that adding obinutuzumab to standard therapy can help some patients maintain better disease control over the one-year study period.
However, the findings do not establish that flares are permanently prevented or that patients can discontinue all other lupus treatment.
What is systemic lupus erythematosus?
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease in which the immune system mistakenly attacks healthy tissues.
The condition can affect multiple parts of the body, including the skin, joints, kidneys, blood cells, heart, lungs and nervous system.
Symptoms vary considerably between patients and can change over time.
Common manifestations include:
- Persistent fatigue;
- Joint pain, stiffness or swelling;
- Skin rashes, sometimes worsened by sunlight;
- Fever during periods of active inflammation;
- Hair loss or mouth ulcers; and
- Symptoms associated with inflammation affecting internal organs.
Lupus disproportionately affects women, although it can occur in people of any sex.
Some patients experience relatively mild disease, while others develop serious organ involvement or recurring flares despite treatment.
Because symptoms overlap with many other conditions, diagnosis may require clinical assessment together with laboratory investigations, including tests for relevant autoantibodies.
How is Gazyvaro different from existing lupus treatments?
Lupus treatment is individualised according to disease activity, organ involvement, previous treatment response and patient-specific risks.
Established approaches may include hydroxychloroquine, corticosteroids, conventional immunosuppressive medicines and selected targeted biological treatments.
Gazyvaro works by depleting CD20-positive B cells, which are involved in the autoimmune processes underlying lupus.
This differs from some other biological treatments used in lupus.
| Treatment | General mechanism | Role in lupus |
|---|---|---|
| Hydroxychloroquine | Modulates immune activity | Common foundational treatment for many patients with SLE |
| Belimumab | Inhibits B-lymphocyte stimulator (BLyS/BAFF) | Targeted add-on therapy for eligible patients with active SLE |
| Anifrolumab | Blocks type I interferon receptor signalling | Targeted treatment for eligible adults with moderate-to-severe SLE |
| Gazyvaro (obinutuzumab) | Depletes CD20-positive B cells | Proposed additional treatment for moderate-to-severe active autoantibody-positive SLE despite standard therapy |
These treatments have different mechanisms, safety profiles and approved indications.
The ALLEGORY trial compared obinutuzumab with placebo alongside standard treatment. It did not establish that Gazyvaro is superior to belimumab, anifrolumab or other targeted lupus therapies in direct head-to-head comparisons.
Further evidence and clinical experience will help determine which patients may benefit most from each approach.
Is Gazyvaro already approved for lupus nephritis?
Yes. Gazyvaro already has an EU indication for certain patients with active lupus nephritis.
Lupus nephritis occurs when lupus-related inflammation affects the kidneys. It can lead to protein leakage into the urine, reduced kidney function and, in severe cases, kidney failure.
The existing European lupus nephritis indication covers specified forms of active disease and involves treatment in combination with mycophenolate mofetil.
The November 2026 recommendation is different.
It would extend Gazyvaro’s use to adults with moderate-to-severe active systemic lupus erythematosus who meet the proposed criteria, rather than limiting the lupus indication to particular forms of kidney involvement.
This distinction matters for patients who have significant systemic lupus activity but do not necessarily meet the existing lupus nephritis indication.
What are the risks and side effects of Gazyvaro?
Gazyvaro affects the immune system by reducing B-cell populations, so infection risk and other treatment-related complications are important considerations.
According to the EMA, the most frequently reported adverse reactions in patients with SLE included upper respiratory tract infections and urinary tract infections.
In the ALLEGORY trial:
- Adverse events were reported in 88.7% of patients receiving obinutuzumab and 81.5% receiving placebo.
- Serious adverse events occurred in 15.9% of patients receiving obinutuzumab and 11.9% receiving placebo.
These figures describe events recorded during the trial and do not mean that every event was caused by the study medicine.
Gazyvaro’s established safety information also includes important precautions related to infusion reactions, serious infections, hepatitis B reactivation and progressive multifocal leukoencephalopathy (PML), a rare but potentially serious brain infection.
Patients may require screening, vaccination review and other precautions before receiving B-cell-depleting treatment.
The final updated European product information will specify how the medicine should be used in the expanded SLE population, including monitoring and contraindications.
Because the treatment is administered by infusion and can affect immune defences, it requires specialist assessment and supervision.
Does Gazyvaro cure lupus?
No. The available evidence does not establish Gazyvaro as a cure for systemic lupus erythematosus.
The ALLEGORY results show that more patients receiving obinutuzumab achieved meaningful reductions in disease activity, and that some achieved remission or low disease activity during the study.
These are important outcomes, but remission is not the same as permanent elimination of the disease.
Lupus is a chronic condition that may fluctuate over time. Patients can experience periods of improved disease control followed by renewed activity.
Longer-term evidence is needed to determine how durable the benefits of obinutuzumab are, how patients respond to repeated treatment and whether improved disease control translates into less cumulative organ damage over many years.
Is Gazyvaro approved for systemic lupus in Europe?
As of 15 November 2026, the broader SLE indication has received a positive EMA committee opinion but not final European Commission authorisation.
The regulatory process involves several stages:
- CHMP scientific assessment: Positive opinion adopted on 12 November 2026.
- European Commission decision: Pending for the expanded SLE indication.
- Updated EU marketing authorisation: Would follow a positive Commission decision.
- National pricing and reimbursement: Decisions made within individual member states.
- Clinical availability: Dependent on local treatment pathways, procurement and access arrangements.
Gazyvaro is already an authorised medicine in the EU for other indications. The outstanding decision concerns extending that authorisation to the wider SLE population.
Patients should not assume that an existing authorisation for another condition automatically means that Gazyvaro is routinely available or reimbursed for systemic lupus.
When will Gazyvaro be available for lupus patients in EU countries?
There is no confirmed EU-wide launch or reimbursement date for the proposed expanded SLE indication.
After a European Commission decision, access may vary between countries according to their healthcare systems and national reimbursement arrangements.
In Germany, France, Italy, Spain, the Netherlands, Ireland, Sweden, Poland, Malta and other EU member states, patients may face different eligibility requirements and funding arrangements.
Because Gazyvaro is already used for other conditions, some hospitals may have experience administering the medicine. However, this does not guarantee that treatment for the new SLE indication will be funded or available immediately.
National assessments may consider clinical benefit, safety, cost-effectiveness, budget impact and how the medicine compares with existing lupus treatments.
Patients should seek information from their rheumatology specialist or local healthcare provider rather than assuming that the EMA recommendation alone establishes entitlement to treatment.
How much will Gazyvaro cost for lupus treatment?
There is currently no confirmed EU-wide patient price or reimbursement arrangement for the proposed broader SLE indication.
Gazyvaro is an existing biological medicine, but the cost of treatment for lupus will depend on national procurement, reimbursement rules, administration costs and individual eligibility.
Hospital-administered biological treatments may be funded through different mechanisms from medicines dispensed directly to patients at community pharmacies.
The EMA recommendation does not establish a new Europe-wide price.
What about Gazyvaro approval in the United States?
Obinutuzumab is marketed as Gazyva in the United States.
The medicine has existing US authorisations for certain conditions, including lupus nephritis.
Roche has also submitted an application to the US Food and Drug Administration seeking to expand its use to systemic lupus erythematosus.
However, a regulatory application is not the same as an approval.
US and EU authorisation decisions, approved indications, prescribing requirements and reimbursement arrangements must be considered separately.
Who might benefit from the proposed treatment?
The proposed European indication is directed at adults who have:
- Moderate-to-severe systemic lupus erythematosus;
- Active disease despite standard therapy;
- Positive tests for relevant autoantibodies; and
- A clinical profile suitable for treatment with obinutuzumab.
Patients with mild or well-controlled lupus may not require this type of additional immunosuppressive treatment.
For patients with persistent disease activity, recurrent flares or difficulty reducing corticosteroids, an additional treatment option may be particularly valuable.
Nevertheless, treatment suitability must be assessed individually, including infection history, previous medicines, organ involvement and other clinical risks.
Frequently asked questions
What is Gazyvaro used for?
Gazyvaro (obinutuzumab) is an anti-CD20 monoclonal antibody already authorised in the EU for certain blood cancers and lupus nephritis. The EMA has now recommended expanding its use to adults with moderate-to-severe active autoantibody-positive systemic lupus erythematosus despite standard treatment.
How effective was Gazyvaro in the ALLEGORY trial?
After 52 weeks, 76.7% of patients receiving obinutuzumab plus standard treatment achieved an SRI-4 response, compared with 53.5% receiving placebo plus standard treatment. The adjusted difference was 23.1 percentage points.
Can Gazyvaro reduce lupus flares?
The ALLEGORY trial reported a significant improvement in time to the first lupus flare among patients receiving obinutuzumab compared with placebo, alongside standard treatment.
Can Gazyvaro help reduce prednisone use?
The Phase 3 trial found that patients receiving obinutuzumab were more likely to achieve sustained glucocorticoid dose reductions while maintaining disease control. Corticosteroid changes must be supervised by a clinician.
Is Gazyvaro the same as rituximab?
No. Both target CD20-positive B cells, but they are different monoclonal antibodies with distinct molecular properties and clinical evidence. They should not be treated as interchangeable medicines.
Is Gazyvaro a cure for lupus?
No. The clinical evidence demonstrates improved disease control in some patients, not permanent elimination of systemic lupus erythematosus.
What are the main safety concerns?
Infections, infusion-related reactions and other complications associated with B-cell depletion are important considerations. The EMA identified upper respiratory and urinary tract infections among the most frequently reported side effects in the SLE population.
Is Gazyvaro already available for systemic lupus in Europe?
The medicine is authorised for other indications, including certain forms of lupus nephritis. However, the broader systemic lupus indication recommended in November 2026 still requires a European Commission decision.
What happens next?
The European Commission will consider the EMA committee’s recommendation and decide whether to extend Gazyvaro’s EU marketing authorisation.
If the expanded indication is approved, updated European prescribing information will be published, followed by national decisions affecting pricing, reimbursement and clinical access.
Further long-term evidence will also be important for understanding the durability of disease control, infection risks and whether reduced lupus activity translates into better long-term organ outcomes.
For patients whose lupus remains active despite standard treatment, the ALLEGORY findings represent a meaningful clinical advance.
The strongest conclusion supported by the evidence is that adding obinutuzumab improved lupus disease control over 52 weeks, with fewer flares and greater opportunity to reduce corticosteroid use. Whether and when patients across Europe can access the treatment will depend on the remaining regulatory and national decisions.
Reviewed by: Dr Mattias Hagman, PhD
Editorial review: MediSearcher reviewed the EMA’s November 2026 recommendation, the formal CHMP positive opinion and the published Phase 3 ALLEGORY trial. Clinical response, remission, safety outcomes and regulatory status are distinguished from claims of cure or confirmed national treatment access.
Last reviewed: 15 November 2026
Sources and verification
- European Medicines Agency: EMA recommends extending Gazyvaro’s use to systemic lupus erythematosus, 13 November 2026 — primary regulatory announcement and patient-relevant summary.
- European Medicines Agency: Gazyvaro positive CHMP opinion, 12 November 2026 — exact proposed EU indication and regulatory status.
- New England Journal of Medicine: Efficacy and Safety of Obinutuzumab in Active Systemic Lupus Erythematosus, 2026 — peer-reviewed Phase 3 ALLEGORY trial results.
- ClinicalTrials.gov: ALLEGORY Phase 3 trial, NCT04963296 — clinical-trial registration and study details.
- European Medicines Agency: Gazyvaro medicine overview — existing EU authorisations and product information.
This article provides general information and does not replace individual medical advice. Lupus is a complex autoimmune disease requiring specialist management. Patients should not change corticosteroids, immunosuppressants or other prescribed treatments without advice from their healthcare professional. Regulatory status and access arrangements may change after publication.